BriaCell Therapeutics Corp. Signs Material Definitive Agreement
Ticker: BCTXZ · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1610820
Sentiment: neutral
Topics: material-agreement, corporate-event
Related Tickers: BCTX
TL;DR
BriaCell signed a big deal, filing shows. Big news for BCTX.
AI Summary
BriaCell Therapeutics Corp. announced on April 24, 2025, that it entered into a material definitive agreement. The company, previously known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the pharmaceutical preparations sector. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new contract or partnership for BriaCell Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, counterparty, and execution of the agreement.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- April 24, 2025 (date) — Date of earliest event reported
- June 13, 2014 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement entered into by BriaCell Therapeutics Corp.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on April 24, 2025.
When was BriaCell Therapeutics Corp. previously known by another name?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp. until June 13, 2014.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is the Standard Industrial Classification (SIC) code for BriaCell Therapeutics Corp.?
The SIC code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date for this 8-K report?
This 8-K report was filed as of April 28, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding BriaCell Therapeutics Corp. (BCTXZ).